Nessan Bermingham
Co-Founder & Independent Chairman of the BoardDr. Nessan Bermingham, also known as Ness, is Director of Amide Technologies, Inc. from October 2025. Dr. Bermingham is Co-founder of Liberate Bio, Inc. He was Operating Partner of Khosla Ventures, LLC since December 2021 until 2026. Dr. Bermingham focuses on life science companies with an emphasis on nucleic acid editing, novel delivery systems, gene and cell therapy, novel target identification and data analytics for drug discovery and development. Dr. Bermingham is a serial biotech entrepreneur and investor. At Intellia, Dr. Bermingham served as president and Chief Executive Officer from 2014 to 2017, leading the company from concept through partner deals, multiple financing rounds and an IPO. He is Board Observer at Eligo Bioscience S.A.S. Dr. Bermingham also held investment roles at Omega Fund Management, where he successfully invested in and managed multiple investments across the United States and Europe. Dr. Bermingham is currently the chairman of F-star and executive chair at Korro Bio. Dr. Bermingham also currently sits on the board of Amide, Bionaut Labs, Deep Genomics, Kamau Therapeutics, Liberate Bio, Ochre Bio and Stylus Biomedicine and is a board observer with Eligo Bioscience. Dr. Bermingham was Founder & Member of Scientific Advisor Board of Intellia Therapeutics, Inc. Dr. Bermingham joined the Intellia Therapeutics, Inc. in May 2014. Dr. Bermingham is Executive Chairman of f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. from September 10, 2018. Dr. Bermingham is Board Observer of Lysosomal Therapeutics, Inc. Dr. Bermingham joined the Lysosomal Therapeutics, Inc. on May 12, 2014. Dr. Bermingham is Director of Deep Genomics Inc. from January 2023. Dr. Bermingham was Venture Partner of Atlas Venture Advisors, Inc. (formerly known as Atlas Venture L.P.). from February 2018 until July 2021. Dr. Bermingham focuses on Life Sciences. Dr. Bermingham was Atlas Advisor, Entrepreneur-in-Residence, Venture Partner, Partner & Advisor of Atlas Venture Advisors, Inc. (formerly known as Atlas Venture L.P.). until 2018. Dr. Bermingham is Co-Founder of Ascelegen Therapeutics, Inc. Dr. Bermingham is Director of Alliance for Regenerative Medicine. Dr. Bermingham is Co-Founder of Korro Bio, Inc. & Independent Chairman since November 03, 2023. Dr. Bermingham founded six biotech companies. Dr. Bermingham was Independent Chairman of F-star Therapeutics, Inc. from May 2019. Dr. Bermingham was Director of F-star Therapeutics, Inc. Dr. Bermingham was Founder of Triplet Therapeutics, Inc. and was its President, CEO & Director from November 2018 until July 2021. Dr. Bermingham was Biopharma Research Analyst of UBS Investment Bank. Dr. Bermingham was Director of Arrow Therapeutics, Ltd. Dr. Bermingham was Director of Cellzome GmbH. He is currently Executive Chairman of EveryONE Medicines, where he served as Interim Chief Executive Officer from October 2022 to July 2024. Dr. Bermingham was Founder and Managing Partner of Bio Equity Capital LLC. Dr. Bermingham was Director of Inspired Capital plc. Dr. Bermingham was employed at Inspired Capital plc from September 01, 2005 to March 24, 2006. Dr. Bermingham has Ph.D. in Molecular Biology from Imperial College, B.S. in genetics from Queens University of Belfast. Dr. Bermingham was a Howard Hughes Associate Fellow at Baylor College of Medicine. He was Director of Xilio Therapeutics (Nasdaq:XLO).
Positions
- Company NameKorro Bio, Inc.Stock CodeKRROPositionCo-Founder & Independent Chairman of the BoardColleagues
- RARam AiyarCEO, President, Interim CFO, Principal Financial Officer & Director
- JFJean-Francois FormelaCo-Founder & Director
- LVLoic VincentChief Scientific Officer
- JMJeffrey M. CerioSenior VP, General Counsel & Corporate Secretary
- AFAndrew FraleyCo-Founder & Advisor
- ABAli BehbahaniIndependent Director
- TRTimothy R. PearsonIndependent Director
